VPI-2690B is a human monoclonal antibody (mAb) targeting Integrin aVb3. VPI-2690B inhibits TGF-beta signaling. VPI-2690B can be used in Diabetic nephropathies research[1].
Target:
Integrin,TGF-beta Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
